Indaptus Therapeutics, INC S-1 registration statements

Indaptus Therapeutics filed an S-1/A to include a new engagement agreement with H.C. Wainwright & Co., detailing multiple recent capital raises totaling over $7 million.

Indaptus Therapeutics, a clinical biotechnology company, filed an S-1 registration statement for a best-efforts public offering of common stock and warrants to raise up to $15 million for R&D and general corporate purposes.

Indaptus Therapeutics registers for the resale of up to 10 million shares of common stock by YA II PN, LTD., potentially raising up to $20 million through a standby equity purchase agreement.

Indaptus Therapeutics is registering for the resale of up to 1,941,229 shares of common stock by selling stockholders, primarily related to warrants issued in recent private placements.

Indaptus Therapeutics is registering for the resale of 1,643,837 shares of common stock issuable upon the exercise of warrants from a recent private placement.